Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213973 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT07213973: Recruiting Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
NCT07213973 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 40 participants, below the 177-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213973, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Primary Outcome
TEAE is defined as any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.
Conditions Studied
Interventions
- DRUG Povorcitinib
Study Locations (20)
Florida
- University of Miami Miller School of Medicine - Miami
- Skin Research of South Florida, Llc - Miami
- Trueblue Clinical Research - Tampa
Michigan
- Oakland Hills Dermatology Pc - Auburn Hills
- Wayne State University Physician Group Dermatology - Detroit
- Revival Research Institute, Llc Troy - Troy
Arizona
- Medical Dermatology Specialists Phoenix - Phoenix
- Saguaro Dermatology - Phoenix
Alabama
- University of Alabama At Birmingham - Birmingham
Connecticut
- Uconn Health - Farmington
Georgia
- Advanced Medical Research Pc - Sandy Springs
Illinois
- Endeavor Health Medical Group - Skokie
Kansas
- Dermatology Skin Cancer Center Leawood - Leawood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2028-03-25 |
| Phase | Phase 2 |
What NCT07213973 shows while recruiting
NCT07213973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 177-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which Povorcitinib is the first listed.
NCT07213973 names 20 study sites across 15 states, led by Florida, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT07213973 about?
NCT07213973 is a clinical study titled "Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
What is the current status of trial NCT07213973?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-02-02. Estimated completion is 2028-03-25.
What conditions does trial NCT07213973 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07213973?
The interventions under investigation include: Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT07213973?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213973 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07213973's enrollment target sits among peer trials
40 7th of 12 higher than 6 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI